Table 1 Risk of lung cancer in women with breast cancer compared to women without breast cancer diagnosis.

From: Risk of primary lung cancer after adjuvant radiotherapy in breast cancer—a large population-based study

 

No. of events

Incidence per 100,000 pyrs

Crude

Adjusteda

HR

95% CI

HR

95% CI

BC

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC

270

138.6

1.34

(1.17–1.54)

1.35

(1.18–1.54)

RT

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC, No RT

52

94.0

0.91

(0.69–1.20)

0.81

(0.62–1.08)

BC, RT

218

156.2

1.52

(1.31–1.76)

1.59

(1.37–1.84)

N-stage

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC N0

181

145.6

1.41

(1.20–1.65)

1.41

(1.20–1.65)

BC N1-3

52

126.4

1.23

(0.93–1.63)

1.29

(0.97–1.70)

BC N4+

13

95.5

0.94

(0.54–1.62)

1.01

(0.58–1.75)

BC NX

24

151.8

1.49

(0.99–2.24)

1.28

(0.85–1.92)

RT/N-stage

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC, No RT

52

94.0

0.91

(0.69–1.20)

0.82

(0.62–1.08)

BC, RT N0

136

160.2

1.55

(1.29–1.85)

1.62

(1.35–1.94)

BC, RT N1-3

46

141.9

1.38

(1.03–1.86)

1.48

(1.10–1.99)

BC, RT N4+

13

106.6

1.04

(0.60–1.81)

1.15

(0.66–1.98)

BC, RT NX

23

229.0

2.24

(1.48–3.39)

2.15

(1.42–3.25)

ER-status

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC, ER+

168

135.0

1.32

(1.12–1.56)

1.28

(1.09–1.51)

BC, ER−

45

149.5

1.44

(1.07–1.94)

1.54

(1.14–2.08)

BC, ER missing

57

141.3

1.34

(1.02–1.75)

1.41

(1.08–1.85)

PR-status

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC, PR+

125

115.1

1.12

(0.93–1.35)

1.11

(0.92–1.34)

BC, PR-

85

191.2

1.87

(1.49–2.33)

1.83

(1.47–2.29)

BC, PR missing

60

143.6

1.36

(1.05–1.77)

1.43

(1.10–1.86)

Endocrine therapy

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC, No Endo

109

132.4

1.26

(1.04–1.54)

1.33

(1.09–1.62)

BC, Endo

161

143.1

1.40

(1.19–1.66)

1.35

(1.15–1.60)

Chemotherapy

No BC

976

103.8

1.00

Ref.

1.00

Ref.

BC, No Chemo

217

146.6

1.41

(1.22–1.64)

1.34

(1.16–1.56)

BC, Chemo

53

113.1

1.11

(0.84–1.47)

1.35

(1.02–1.78)

  1. Hazard ratios (HR) for lung cancer (LC) conditioned on 5-year event-free survival. Restricted to women undergoing surgery for breast cancer (BC) and their comparison women without BC diagnosis. Number (No.), incidence (Inc.), person years (pyrs), reference (Ref.) radiotherapy (RT), pathological lymph node stage (N-status), estrogen receptor status (ER-status), progesterone receptor status (PR-status), endocrine therapy (endo), chemotherapy (chemo), and Charlson comorbidity index (CCI).
  2. aAdjusted for age, year of BC, educational level, chronic pulmonary disease (CPD), and CCI except CPD.
Back to article page